Sam Brusco, Associate Editor04.30.24
Xtant Medical has initiated the full commercial launch of two amniotic membrane allografts, SimpliGraft and SimpliMax.
SimpliGraft and SimpliMax are dehydrated, terminally irradiated, single- and dual-layer amniotic membrane sheets. The products serve as a barrier and offer protective coverage from the surrounding environment when topically applied to both chronic and acute wounds.
The membrane sheets are manufactured at Xtant’s center for biologicas processing in Belgrade, Montana. The release of the two products marks the company’s entry into the wound care market.
Xtant said it plans to market these two new offerings through its nationwide distribution network of independent agents, as well as adjacent market segments through OEM relationships. The launch, according to the company, is a testament to its advancement in bio-manufacturing.
“The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, president and CEO of Xtant Medical. “We expect our new product launches and robust product pipeline will position Xtant as a leader and innovator in the field of advanced biologic therapies.”
Xtant was quite active in M&A transactions in 2023. It acquired Surgalign’s Coflex interlaminar stabilization device and Cofix supplemental fixation device in March 2023, and Surgalign’s spinal hardware and biologics businesses in August. Xtant also purchased RTI Surgical’s nanOss orthobiologic production operations in October 2023.
SimpliGraft and SimpliMax are dehydrated, terminally irradiated, single- and dual-layer amniotic membrane sheets. The products serve as a barrier and offer protective coverage from the surrounding environment when topically applied to both chronic and acute wounds.
The membrane sheets are manufactured at Xtant’s center for biologicas processing in Belgrade, Montana. The release of the two products marks the company’s entry into the wound care market.
Xtant said it plans to market these two new offerings through its nationwide distribution network of independent agents, as well as adjacent market segments through OEM relationships. The launch, according to the company, is a testament to its advancement in bio-manufacturing.
“The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, president and CEO of Xtant Medical. “We expect our new product launches and robust product pipeline will position Xtant as a leader and innovator in the field of advanced biologic therapies.”
Xtant was quite active in M&A transactions in 2023. It acquired Surgalign’s Coflex interlaminar stabilization device and Cofix supplemental fixation device in March 2023, and Surgalign’s spinal hardware and biologics businesses in August. Xtant also purchased RTI Surgical’s nanOss orthobiologic production operations in October 2023.